Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LT3001 in Acute Ischemic Stroke
NCT05686642Phase 2Recruiting
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Apr 2023
- Primary completion
- Dec 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of odatroltide in ischemic stroke, sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Started Apr 2023; status: recruiting.
02
Drugs
odatroltide
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05686642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05686642.